Context Therapeutics Investor Presentation Deck

CLDN6xCD3 Bispecific Antibody Program We have developed a library of CLDN6xCD3 bispecifics Explored a range of bispecific frameworks, CLDN6 sequences, and CD3 sequences Comparator bispecifics generated for benchmarking Candidate selection on track for Q4 2022 • ● • 18 Context Therapeutics Inc. - Sept. 2022 YY Highly specific CLDN6 MAbs generated by Integral Molecular a-CLDN6 Y Well characterized anti-CD3y8 partner arms CLDN6xCD3 Bispecific Antibody Program a-CD3 Rucker et al., Development of CLDN6 bispecific antibodies for treatment of ovarian cancer, AACR 2022

View entire presentation